Search Result

Results for "

tumour growth

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (1) FGFR (1) TGF-beta/Smad (2) TGF-β Receptor (4) Akt (1) Apoptosis (8) CDK (3) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (3) Epigenetic Reader Domain (1) FAK (1) Fluorescent Dye (1) HSV (1) JAK (1) Mitochondrial Metabolism (2) MMP (1) NAMPT (1) Nucleoside Antimetabolite/Analog (1) P2X Receptor (1) Parasite (1) PI3K (1) PROTACs (2) Reactive Oxygen Species (1) Sodium Channel (5) Src (1) TRP Channel (1) Virus Protease (5)
By Research Areas:	Cancer (32) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (5)

By Targets:

EGFR (1)

FGFR (1)

TGF-beta/Smad (2)

TGF-β Receptor (4)

Akt (1)

Apoptosis (8)

CDK (3)

DNA Alkylator/Crosslinker (2)

DNA/RNA Synthesis (3)

Epigenetic Reader Domain (1)

FAK (1)

Fluorescent Dye (1)

HSV (1)

JAK (1)

Mitochondrial Metabolism (2)

MMP (1)

NAMPT (1)

Nucleoside Antimetabolite/Analog (1)

P2X Receptor (1)

Parasite (1)

PI3K (1)

PROTACs (2)

Reactive Oxygen Species (1)

Sodium Channel (5)

Src (1)

TRP Channel (1)

Virus Protease (5)

By Research Areas:

Cancer (32)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: FGFR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR EGFR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-B0448

Phenytoin 4 Publications Verification 5,5-Diphenylhydantoin	Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-B0448A

Phenytoin sodium 4 Publications Verification 5,5-Diphenylhydantoin sodium salt	Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin sodium (5,5-Diphenylhydantoin sodium salt) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-150966

Antiproliferative agent-10	Mitochondrial Metabolism
Antiproliferative agent-10 (compound 8) is an anti-tumour ruthenium(II)-tris-pyrazolylmethane complex that inhibits the growth of cancer cells by inhibiting mitochondrial calcium uptake .

HY-150969

Antiproliferative agent-12	Mitochondrial Metabolism	Cancer
Antiproliferative agent-10 (compound 1) is an anti-tumour ruthenium(II)-tris-pyrazolylmethane complex that inhibits the growth of cancer cells by inhibiting mitochondrial calcium uptake .

HY-16293

Lurbinectedin 2 Publications Verification PM01183; LY-01017	DNA Alkylator/Crosslinker DNA/RNA Synthesis	Cancer
Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC₅₀ values of 1.25 and 1.16 nM, respectively.

HY-103244

CITCO 1 Publications Verification	Apoptosis	Cancer
CITCO, an imidazothiazole derivative, is a selective Constitutive androstane receptor (CAR) agonist. CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC₅₀ of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors .

HY-B0448S

Phenytoin-d10 5,5-Diphenylhydantoin-d₁₀	Sodium Channel Virus Protease	Neurological Disease
Phenytoin-d₁₀ is the deuterium labeled Phenytoin. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice[1][2].

HY-151101

MS159	PROTACs	Cancer
MS159 is a potent nuclear receptor binding SET structural domain protein 2 (NSD2) PROTACdegrader. MS159 inhibits the growth of tumour cells. MS159 is a useful chemical tool for exploring the role of NSD2 in health and disease .

HY-14375

CB 300919	NAMPT	Cancer
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft .

HY-107194

NSC12	FGFR	Cancer
NSC 12 is an extracellular trap of fibroblast growth factor 2 (FGF2) that binds FGF2 and interferes with its interaction with FGFR1. NSC12 inhibits the proliferation of different FGF-dependent tumour cells both in vitro and in vivo with no systemic toxic effects .

HY-B0448R

Phenytoin (Standard)	Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin (Standard) is the analytical standard of Phenytoin. This product is intended for research and analytical applications. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-16293S

Lurbinectedin-d3 PM01183-d₃; LY-01017-d₃	DNA Alkylator/Crosslinker DNA/RNA Synthesis	Cancer
Lurbinectedin-d₃ is deuterium labeled Lurbinectedin. Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively[1].

HY-139109

IR-783 ADS 780WS	Fluorescent Dye Apoptosis	Others
IR-783 (ADS 780WS) is a near-infrared (NIR) heptamethine cyanine fluorescent probe. IR-783 significantly inhibits tumour growth and induces apoptosis in MDA-MB-231 xenograft model. IR-783 can be used to study breast cancer .

HY-B0448S1

Phenytoin-15n2,13c	Sodium Channel Virus Protease
Phenytoin- ¹⁵N₂, ¹³C is the ¹³C and ¹⁵N labeled Phenytoin[1]. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice[2][3].

HY-108669

AZ10606120 dihydrochloride 1 Publications Verification	P2X Receptor	Neurological Disease Cancer
AZ10606120 dihydrochloride is a selective, high affinity antagonist for P2X7 receptor (P2X7R) at human and rat with an IC₅₀ of about 10 nM. AZ10606120 dihydrochloride is little or no effect at other P2XR subtypes. AZ10606120 dihydrochloride has anti-depressant effects and reduces tumour growth .

HY-100549

(S)-Crizotinib	DNA/RNA Synthesis Apoptosis	Cancer
(S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC₅₀ of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models .

HY-152182

ML-SA5 1 Publications Verification	TRP Channel	Cancer
ML-SA5 is a potent TRPML1 cation channel agonist that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC₅₀ of 285 nM and is more potent than ML-SA1. ML-SA5 has anticancer activity and can inhibit tumour growth .

HY-146354

Antiproliferative agent-4	Apoptosis Reactive Oxygen Species	Cancer
Antiproliferative agent-4 (compound 2y) has excellent anti-proliferative activity against certain cancer cell lines. Antiproliferative agent-4 reduces the mitochondrial membrane potential, and increases the apoptosis rate and the level of ROS on EC109. Antiproliferative agent-4 inhibits tumour growth in nude mice, with low toxicity .

HY-113604

Pentabromopseudilin	TGF-β Receptor	Cancer
Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour and phytotoxic activities. PBrP is a reversible and allosteric inhibitor of myosin Va (MyoVa). PBrP also is a potent inhibitor of *transforming growth* factor-β (TGF-β)** activity. PBrP can be used for the research of fibrotic diseases and cancer .

HY-145388

AU-15330 3 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (compound Ex-05) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151281

ALK5-IN-31	TGF-β Receptor	Cancer
ALK5-IN-31 (compound Ex-08) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151606

Akt3 degrader 1	Akt	Cancer
Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .

HY-151282

ALK5-IN-32	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-32 (compound EX-09) is a selective ALK-5 inhibitor (10 nM<IC₅₀<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-18684

SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine	Nucleoside Antimetabolite/Analog HSV Parasite	Infection Metabolic Disease Cancer
SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies .

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 ^V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .

HY-150562

CDK9-IN-19	CDK	Cancer
CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .

HY-119944

JND3229	EGFR	Cancer
JND3229 is a reversible EGFR ^C797S inhibitor with IC₅₀ values of 5.8, 6.8 and 30.5 nM for EGFR ^{L858R/T790M/C797S}, EGFR ^WT and EGFR ^L858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma .

HY-120213

YH-306	FAK Src PI3K MMP Apoptosis	Cancer
YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization .

IR-783 ADS 780WS	Biochemical Assay Reagents
IR-783 (ADS 780WS) is a near-infrared (NIR) heptamethine cyanine fluorescent probe. IR-783 significantly inhibits tumour growth and induces apoptosis in MDA-MB-231 xenograft model. IR-783 can be used to study breast cancer .

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

YIGSR Laminin Fragment 929-933	Peptides	Cancer
YIGSR is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells .

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

Labetuzumab	Inhibitory Antibodies	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

ATG-031 1 Publications Verification	Inhibitory Antibodies	Cancer
ATG-031 is a humanised anti-CD24 monoclonal antibody. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the "don't eat me" signals that characterize the growth of many cancers. ATG-031 can be used in the study of haematological malignancies as well as solid tumours.

Cat. No.	Product Name	Category	Target	Chemical Structure